Zai Lab Management
Management criteria checks 3/4
Zai Lab's CEO is Samantha Du, appointed in Jan 2014, has a tenure of 10.33 years. total yearly compensation is $12.04M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.13% of the company’s shares, worth $18.47M. The average tenure of the management team and the board of directors is 3.6 years and 5.6 years respectively.
Key information
Samantha Du
Chief executive officer
US$12.0m
Total compensation
| CEO salary percentage | 7.2% |
| CEO tenure | 10.3yrs |
| CEO ownership | 1.1% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?
May 18Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses
Mar 08Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates
Mar 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$12m | US$869k | -US$335m |
| Sep 30 2023 | n/a | n/a | -US$301m |
| Jun 30 2023 | n/a | n/a | -US$393m |
| Mar 31 2023 | n/a | n/a | -US$410m |
| Dec 31 2022 | US$20m | US$830k | -US$443m |
| Sep 30 2022 | n/a | n/a | -US$593m |
| Jun 30 2022 | n/a | n/a | -US$529m |
| Mar 31 2022 | n/a | n/a | -US$554m |
| Dec 31 2021 | US$15m | US$774k | -US$704m |
| Sep 30 2021 | n/a | n/a | -US$569m |
| Jun 30 2021 | n/a | n/a | -US$537m |
| Mar 31 2021 | n/a | n/a | -US$454m |
| Dec 31 2020 | US$9m | US$689k | -US$269m |
| Sep 30 2020 | n/a | n/a | -US$239m |
| Jun 30 2020 | n/a | n/a | -US$240m |
| Mar 31 2020 | n/a | n/a | -US$201m |
| Dec 31 2019 | US$9m | US$656k | -US$195m |
| Sep 30 2019 | n/a | n/a | -US$212m |
| Jun 30 2019 | n/a | n/a | -US$181m |
| Mar 31 2019 | n/a | n/a | -US$160m |
| Dec 31 2018 | US$6m | US$638k | -US$139m |
Compensation vs Market: Samantha's total compensation ($USD12.04M) is above average for companies of similar size in the US market ($USD5.72M).
Compensation vs Earnings: Samantha's compensation has been consistent with company performance over the past year.
CEO
Samantha Du (57 yo)
10.3yrs
Tenure
US$12,042,285
Compensation
Dr. Ying Du, Ph D., also known as Samantha, serves as Founding Managing Director at Quan Capital. She served as Venture Partner at Sequoia Capital China.Dr. Du serves as an adjunct professor at Fudan Univ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.3yrs | US$12.04m | 1.13% $ 18.5m | |
| President & COO | 1.8yrs | US$5.55m | 0.029% $ 475.9k | |
| President and Head of Global Oncology Research & Development | 1.3yrs | US$4.87m | 0.024% $ 390.4k | |
| Chief Financial Officer | less than a year | US$2.01m | 0.0097% $ 159.5k | |
| President and Head of Global Development for Neuroscience | 7.3yrs | US$4.12m | 0.052% $ 859.3k | |
| Chief Scientific Officer | 1.5yrs | no data | no data | |
| Senior VP & Head of Investor Relations | less than a year | no data | no data | |
| Chief Legal Officer & Joint Corporate Secretary | 3.8yrs | US$5.63m | 0.027% $ 438.1k | |
| Chief Compliance Officer | 3.5yrs | no data | no data | |
| Executive VP & Head of Clinical Operations | 10.3yrs | no data | no data | |
| Chief Business Officer | 10.3yrs | no data | no data | |
| Chief Operating Officer of R&D | 9.3yrs | no data | no data |
3.6yrs
Average Tenure
57yo
Average Age
Experienced Management: ZLAB's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.3yrs | US$12.04m | 1.13% $ 18.5m | |
| Independent Director | 4.3yrs | US$574.35k | 0.041% $ 672.1k | |
| Independent Director | 7.3yrs | US$576.15k | 0.37% $ 6.0m | |
| Lead Independent Director | 7.3yrs | US$608.44k | 0.069% $ 1.1m | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Director | 2.6yrs | US$570.77k | 0.027% $ 435.5k | |
| Independent Director | 5.6yrs | US$567.03k | 0.043% $ 700.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 2.5yrs | US$564.98k | 0.028% $ 461.5k | |
| Independent Director | 5.8yrs | US$557.48k | 0.048% $ 784.3k | |
| Member of Scientific Advisory Board | 4.4yrs | no data | no data |
5.6yrs
Average Tenure
66.5yo
Average Age
Experienced Board: ZLAB's board of directors are considered experienced (5.6 years average tenure).